Literature DB >> 3050149

Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.

H G Kräusslich1, H Schneider, G Zybarth, C A Carter, E Wimmer.   

Abstract

We expressed the gag and proteinase regions of human immunodeficiency virus (HIV) type 1 by transcription and translation in vitro. A synthetic RNA spanning the gag and pro domains gave primarily the unprocessed capsid precursor pr53. Efficient cleavage of this precursor was observed when the gag and pro domains were placed in the same translational reading frame, yielding equimolar amounts of the gag protein and of proteinase (PR). Expression of HIV type 1 PR in Escherichia coli as a fusion protein gave rapid autocatalytic processing to an HIV-specific protein of approximately 11 kilodaltons. HIV PR generated in E. coli specifically induced cleavage of the HIV capsid precursor, whereas deletion of the carboxy-terminal 17 amino acids of the proteinase rendered it inactive. Inhibitor studies showed that the enzyme was insensitive to inhibitors of serine and cysteine proteinases and metalloproteinases and was inhibited only by a very high concentration (1 mM) of pepstatin A.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3050149      PMCID: PMC253881          DOI: 10.1128/JVI.62.11.4393-4397.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Biochemical properties of p15-associated protease in an avian RNA tumor virus.

Authors:  K J Dittmar; K Moelling
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

Review 2.  Viral proteinases.

Authors:  H G Kräusslich; E Wimmer
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

3.  Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.

Authors:  S van der Werf; J Bradley; E Wimmer; F W Studier; J J Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

4.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease.

Authors:  R A Kramer; M D Schaber; A M Skalka; K Ganguly; F Wong-Staal; E P Reddy
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

5.  Pepstatin, a new pepsin inhibitor produced by Actinomycetes.

Authors:  H Umezawa; T Aoyagi; H Morishima; M Matsuzaki; M Hamada
Journal:  J Antibiot (Tokyo)       Date:  1970-05       Impact factor: 2.649

6.  Bovine leukemia virus protease: purification, chemical analysis, and in vitro processing of gag precursor polyproteins.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; G W Smythers; S Oroszlan
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

7.  Nucleotide sequence of SRV-1, a type D simian acquired immune deficiency syndrome retrovirus.

Authors:  M D Power; P A Marx; M L Bryant; M B Gardner; P J Barr; P A Luciw
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

8.  Translational readthrough of an amber termination codon during synthesis of feline leukemia virus protease.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Cooperative dimeric and tetrameric clam haemoglobins are novel assemblages of myoglobin folds.

Authors:  W E Royer; W E Love; F F Fenderson
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

10.  Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

View more
  43 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Preparation and crystallization of a human immunodeficiency virus p24-Fab complex.

Authors:  A J Prongay; T J Smith; M G Rossmann; L S Ehrlich; C A Carter; J McClure
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Commitment to apoptosis in CD4(+) T lymphocytes productively infected with human immunodeficiency virus type 1 is initiated by lysosomal membrane permeabilization, itself induced by the isolated expression of the viral protein Nef.

Authors:  Mireille Laforge; Frederic Petit; Jérôme Estaquier; Anna Senik
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

5.  Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1.

Authors:  K Partin; G Zybarth; L Ehrlich; M DeCrombrugghe; E Wimmer; C Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

6.  Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers.

Authors:  H Burstein; D Bizub; A M Skalka
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 7.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

8.  Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.

Authors:  H G Kräusslich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 9.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

10.  Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase.

Authors:  K Partin; H G Kräusslich; L Ehrlich; E Wimmer; C Carter
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.